Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo

Group 1: Clinical Trial Results - Eli Lilly's TOGETHER-PsO trial showed that 27.1% of participants receiving Taltz and Zepbound achieved complete skin clearance and at least 10% weight loss, compared to 5.8% for Taltz alone, meeting the primary endpoint [2] - The combination of Taltz and Zepbound resulted in a 40% relative increase in the proportion of patients achieving PASI 100 compared to Taltz monotherapy (40.6% vs. 29%) [2] Group 2: Licensing Agreement - CSL Limited entered into an exclusive licensing agreement with Eli Lilly for the development and commercialization of clazakizumab, with an upfront payment of $100 million and potential milestone payments and royalties on global net sales [4] - CSL retains exclusive rights to develop clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Lilly will explore additional indications [5] Group 3: Stock Performance - The stock is currently trading 2.7% below its 20-day simple moving average and 3.2% below its 50-day simple moving average, indicating short-term weakness, but remains 4.3% above its 100-day simple moving average and 17.6% above its 200-day simple moving average, suggesting longer-term strength [7] - The RSI is at 48.22, indicating neutral territory, while the MACD shows bearish pressure with a value of -5.0984 below its signal line of -3.9365 [8]